|Articles|April 10, 2008

Abatacept approved by FDA for use in children

Bristol-Myers Squibb granted approval for arthritis biologic Orencia.

Children ages six years and older with moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) may now get some relief from using abatacept (

Newsletter

Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.

Subscribe Now!

Related Content